Recarbrio — Medicare Part D Spending

Generic: Imipenem/Cilastatin/Relebactam | Manufacturer: Overall

2023 Spending

$1.1M

2023 Claims

181

2023 Beneficiaries

Cost/Unit (2023)

$118.43

5-Year Spending Trend (2019-2023)

Year	Total Spending	Claims	Beneficiaries	Cost/Unit
2019	N/A	N/A	N/A	N/A
2020	$180.0K	66	N/A	$6.31
2021	$941.9K	172	26	$28.15
2022	$1.1M	196	30	$25.07
2023	$1.1M	181	32	$118.43

5Y CAGR (cost/unit): 165.8%YoY Change (2022-2023): 372.4%

Spending by State

State	Total Drug Cost	Claims	Prescribers	Beneficiaries
New York	$192.5K	28	5	N/A
Illinois	$166.5K	30	5	N/A
California	$114.8K	17	4	N/A
Florida	$106.1K	16	2	N/A
Texas	$29.0K	19	4	N/A

📊

DrugPricePeek Editorial TeamData Specialists

The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.

✓ Sourced from CMS NADAC & Medicare Part D✓ Quarterly review✓ No paid placements

Read our full methodology or contact us with corrections.

Frequently Asked Questions

How much does Medicare spend on Recarbrio?

In 2023, Medicare Part D spent $1.1M on Recarbrio (Imipenem/Cilastatin/Relebactam), serving 32 beneficiaries across 181 claims.

What is the cost per unit of Recarbrio under Medicare?

The weighted average cost per dosage unit of Recarbrio was $118.43 in 2023. The 5-year compound annual growth rate (2019-2023) was 165.8%.

Who manufactures Recarbrio?

Recarbrio (generic name: Imipenem/Cilastatin/Relebactam) is manufactured by Overall. There are 1 manufacturer(s) listed in the CMS database for this drug.

Is Recarbrio covered by Medicare Part D?

Yes, Recarbrio is included in Medicare Part D spending data, indicating it is covered by Part D plans. However, specific coverage and tier placement vary by plan. Check with your specific Part D plan for formulary details.

Where does this Medicare spending data come from?

All Medicare Part D spending data comes from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Spending by Drug dataset, which is publicly available at data.cms.gov.

Explore More Data Tools

For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.

Year

Total Spending

Claims

Beneficiaries

Cost/Unit

2019

N/A

2020

$180.0K

N/A

$6.31

2021

$941.9K

172

$28.15

2022

$1.1M

196

$25.07

2023

$1.1M

181

$118.43

State

Total Drug Cost

Claims

Prescribers

Beneficiaries

New York

$192.5K

N/A

Illinois

$166.5K

N/A

California

$114.8K

N/A

Florida

$106.1K

N/A

Texas

$29.0K

N/A

Frequently Asked Questions

How much does Medicare spend on Recarbrio?

In 2023, Medicare Part D spent $1.1M on Recarbrio (Imipenem/Cilastatin/Relebactam), serving 32 beneficiaries across 181 claims.

What is the cost per unit of Recarbrio under Medicare?

The weighted average cost per dosage unit of Recarbrio was $118.43 in 2023. The 5-year compound annual growth rate (2019-2023) was 165.8%.

Who manufactures Recarbrio?

Recarbrio (generic name: Imipenem/Cilastatin/Relebactam) is manufactured by Overall. There are 1 manufacturer(s) listed in the CMS database for this drug.

Is Recarbrio covered by Medicare Part D?

Where does this Medicare spending data come from?

All Medicare Part D spending data comes from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Spending by Drug dataset, which is publicly available at data.cms.gov.